Clinical Trials

Trial Name Description
MA.39 Dr. Francisco Perera
"not yet open" TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer.
PET ABC Dr. Phillip Blanchette
Impact of 18F-FDG PET-CT versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer.
MAC.19 Dr. Steven Latosinsky
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
MAC.21 BR Dr. J. Raphael
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
NSABP B51 BR Dr. S. Latosinsky
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically
REaCT G2 BR Dr. R. Fernandes
A Multi Center Study to Compare Administration Schedules of G-CSF (filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Neutropenia in Early Stage Breast Cancer
DUCHESS Dr. Francisco Perera
Evaluation of the Ductal Carcinoma in Situ Score for Decisions on Radiotherapy in Patients with Low/Intermediate Risk DCIS
MAC.20 Dr. Phillip Blanchette
Randomized Phase III trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer.
TreatER+ight BR Dr. T. Vandenberg
Treatment of Canadian Postmenopausal Women with ER+ Advanced Breast Cancer in the Real-World Setting with Hormone Therapy +/- Targeted Therapy
MRI B-mets BR Dr. F. Perera
Magnetic Imaging of Brain Metastases in Breast Cancer Patients, a Pilot Study of the Value of the balanced steady state free precession imaging (bSSFP) sequence in Detecting Additional Brain Metastases
NRG BR002 Dr. Brian Yaremko
A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer.
REaCT-BTA Dr. Phillip Blanchette
A pragmatic randomized, multicentre trail comparing 4-weekly versus 12-weekly administration of bone-targeted agents in patients with bone metastases from either castration-resistant prostate cancer or breast cancer - The REaCT-BTA Study.
IMpassion BR Dr. T. Vandenberg
A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locall

This information is updated by the Clinical Research Unit

LHSCResearch & Training

Last Updated August 3, 2007 | © 2007, LHSC, London Ontario Canada